Regeneron Pharmaceuticals, Inc. (REGN) News Today: Latest Market and Industry Updates
662.61
5.4100
0.81 %
Real-time price
10:45
USD
Daily range
659.26
662.09
662.09
Weekly range
637.72
677.92
677.92
Regeneron Pharmaceuticals shares gain over 4% as technical momentum and upside gap attract buyers
Regeneron Pharmaceuticals, Inc. (REGN) jumped 4.03% today as strong technical momentum and a decisive upside gap fueled buying interest. However, the move appears limited with price action ...
Buying pressure lifts Regeneron Pharmaceuticals stock higher in today's trading
Regeneron Pharmaceuticals, Inc. (REGN) gained 2.54% today amid a firm intraday tone and technical buying, with prices holding above the 20-day moving average. The up move is limited, as the stock ...
FDA and EMA accept Regeneron's myasthenia gravis therapy filings
Regeneron Pharmaceuticals announced that the U.S. FDA and EMA have accepted regulatory submissions for review of its novel siRNA investigational medicine for adult patients with generalized ...
What is behind Regeneron Pharmaceuticals stock's recent gain in value today
Regeneron Pharmaceuticals, Inc. (REGN) closed at $616.40 after rising 2.73% for the session. The stock trades below all major moving averages, highlighting ongoing downward pressure across short-, ...
Regeneron Pharmaceuticals stock price forecast: $588.98 support in focus as REGN slides 3.86%
Regeneron Pharmaceuticals (REGN) stock is trading at $611.01 after losing 3.86% on the day, underperforming across key moving averages on a pronounced sell-off and ...
Regeneron Pharmaceuticals shares dip amid rising selling pressure
Regeneron Pharmaceuticals (REGN) is trading well below its 20-day, 50-day, and 200-day simple moving averages, with the current price at $603.04 compared to $675.81, $719.37, and $694.72 ...
Regeneron Pharmaceuticals stock consolidates as Global Capability Centre opening in Hyderabad draws focus
Regeneron Pharmaceuticals (REGN) stock is trading at $639.22, posting a minimal daily gain of 0.09%. The price remains well below its key moving averages, indicating it ...
Regeneron stock price forecast: consolidation likely as REGN faces resistance below recent highs
Regeneron received approval for its treatment as the first targeted medicine for certain adults with bullous pemphigoid in Japan.The company announced the news in a tweet and included a link for ...
Regeneron Pharmaceuticals gains FDA approval for allergy treatment
Regeneron Pharmaceuticals has announced that the U.S. FDA has approved its medicine for the treatment of allergic fungal rhinosinusitis (AFRS) in patients aged 6 or older. This development marks ...
Regeneron Pharmaceuticals showcases 36 breakthroughs at AAAAI26
Regeneron Pharmaceuticals is showcasing their latest advances in immunology and inflammation at the AAAAI26 conference. The company is presenting 36 abstracts, including first-time Phase 3 ...
Regeneron Pharmaceuticals partners with Tessera Tx on genetic breakthrough
Regeneron Pharmaceuticals has announced a significant collaboration with Tessera Therapeutics, aiming to revolutionize genomic medicine. The partnership will integrate Regeneron's expertise in ...
Regeneron Pharmaceuticals unveils new blood cancer data at ASH25
Regeneron Pharmaceuticals has introduced new and updated findings from its hematology portfolio at ASH25. This presentation aims to highlight innovative potential approaches across a range of ...
Regeneron unveils Phase 2 data in The Lancet improving heart health
Regeneron Pharmaceuticals has released Phase 2 data on its novel investigational factor XI antibodies, marking a significant step in heart health research. The data was published in The Lancet and ...
